THC Therapeutics EBIT

THC Therapeutics (THCT) currently reports a EBIT of $-490K as of April 2024. That compares with $46K in the prior-year period — down 1166.3% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore THC Therapeutics's EBIT history and peer comparisons.

THC Therapeutics's EBIT decreased from $46K to $-490K — a 1166.3% year-over-year decrease (period ending April 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

THC Therapeutics's EBIT of $-490K is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

THC Therapeutics reported $-490K in EBIT as of April 2024. That compares with $46K in the prior-year period — down 1166.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-490K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for THC Therapeutics, and consider following THCT for alerts when major investors trade the stock.